Lorlatinib Combinations in Lung Cancer

NCT04292119 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

96

Enrollment

OTHER

Sponsor class

Conditions

Lung Cancer
Anaplastic Lymphoma Kinase Gene Translocation
ROS1 Rearrangement
Relapsed Cancer
MET Amplification
Resistant Cancer
NSCLC

Interventions

DRUG: Lorlatinib
DRUG: Crizotinib
DRUG: Binimetinib
DRUG: TNO155

Sponsor

Massachusetts General Hospital

Collaborators

[object Object]
[object Object]